Depression Relief, Not Pain Control, Drives Improvement in Fibromyalgia Patients With Emotional Distress: Study Finds
Taiwan: A new prospective study published in Seminars in Arthritis and Rheumatism has found that in patients with fibromyalgia (FM) and marked psychological distress, improvement in depression—rather than pain relief alone—was the key driver of overall disease improvement. The research, led by Kuo-Wei Lee from the School of Medicine, College of Medicine, Kaohsiung Medical University, Taiwan, highlights the need for early psychiatric evaluation and targeted management in fibromyalgia care.
Fibromyalgia is characterized by widespread musculoskeletal pain, but emotional symptoms such as anxiety and depression are also common. However, the extent to which these psychological factors influence disease severity and treatment response has remained uncertain.
To explore this, the investigators prospectively enrolled 112 individuals newly diagnosed with fibromyalgia and 110 healthy controls at a hospital in Taiwan between June 2021 and December 2022. All patients received pregabalin (75 mg twice daily), with some additionally prescribed imipramine (25 mg once daily). Participants were followed for at least one month, with a mean follow-up duration of nine months. Clinical assessments were conducted at baseline and repeated at two and four weeks to evaluate treatment response.
Validated tools were used to measure symptoms and disease burden, including the Hospital Anxiety and Depression Scale for psychological symptoms, the Numeric Rating Scale for pain intensity, the Widespread Pain Index, and the Revised Fibromyalgia Impact Questionnaire. The primary endpoint was the change in overall fibromyalgia severity.
Based on psychological symptom burden, patients were divided into two subgroups: those with prominent anxiety and depression (FM-AD, n=53) and those without significant emotional distress (FM-nAD, n=59).
Key Findings:
- At baseline, patients in the FM-AD group had significantly higher pain intensity and greater disease severity than those in the FM-nAD group.
- Following initial treatment, pain scores remained significantly higher in the FM-AD group, suggesting a poorer therapeutic response.
- In the overall study population, a reduction in pain was significantly associated with improvement in disease severity.
- Among patients with prominent psychological symptoms, remission of depression was the only significant predictor of clinical improvement.
- In this subgroup, pain reduction was not statistically significantly associated with improvement in disease severity.
- Mediation analysis indicated that relief of depression had a direct beneficial effect on disease outcomes, independent of pain reduction.
The findings suggest that fibromyalgia presents with distinct phenotypes depending on emotional burden. Patients with significant anxiety and depression experienced more severe disease and less favorable therapeutic outcomes. For this subgroup, addressing depression early in the treatment course may be essential to achieving meaningful clinical improvement.
The authors emphasized that pain control alone may not be sufficient in fibromyalgia patients with coexisting psychological distress. Instead, prompt identification and active management of depressive symptoms could help stratify patients and guide more individualized treatment strategies, ultimately improving outcomes in this complex condition.
Reference:
Lee, K., Fong, Y., Lin, Y., Liang, F., Wu, M., Lai, C., & Hung, C. (2026). Alleviation of depression rather than pain predicts disease improvement in fibromyalgia patients with prominent psychological symptoms–a prospective observational study. Seminars in Arthritis and Rheumatism, 77, 152920. https://doi.org/10.1016/j.semarthrit.2026.152920
Next Story